The Latest Breaking News from FDA

A federal judge in Texas has thrown into jeopardy the most common method of abortion in the U.S., ordering regulators to temporarily halt their approval of the drug mifepristone for abortion

A federal judge in Texas will halt the FDA’s approval of mifepristone in seven days unless an appeals court intervenes. But the decision was quickly contradicted by a separate ruling, setting up more legal challenges

The U.S. Food and Drug Administration finalized a regulation in early March 2023 that updates mammography reporting requirements. The new regulation goes into effect on Sept. 10, 2024, and will require that all women receive information about breast density following a mammogram. It will also require they be told in…

Litigation over abortion drugs turns disagreements about individual rights into a bureaucratic tussle.

The Food and Drug Administration (FDA) has warned people not to consume a certain lot of roasted nori seaweed products due to potential contamination of cadmium.

The drug had been fast-tracked for approval under the agency's accelerated approval program, and has been available for more than a decade, despite the drugmaker's failure to prove that it works.

The candy manufacturer defended using the food dye on the basis that it is ‘currently an approved colourant for use in candy by the FDA’

Recent banking turmoil and rising interest rates have weighed heavily on investors’ sentiment lately. However, weak economic data signaling slowing growth could result in relatively easy monetary policies in the second half of 2023. Given the macroeconomic backdrop, investors could consider adding fundamentally sound low P/E stocks Pfizer (PFE), Chevron…

The Food and Drug Administration is ordering an unproven drug intended to prevent premature births off the market